BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 04, 2010
 |  BC Week In Review  |  Company News  |  Deals

Athersys, Pfizer deal

Athersys granted Pfizer rights to develop and commercialize Athersys' MultiStem to treat inflammatory bowel disease (IBD). The therapy composed of multipotent adult progenitor cells (MAPC) based on...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >